Clinical Trial Update: Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for Triac therapy in MCT8 deficiency (Allan-Herndon-Dudley Syndrome) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allan-herndon-dudley Syndrome
• Mct8 Deficiency

Drugs mentioned

• Triac (tiratricol)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Allan-Herndon-Dudley Syndrome | Phase 2 | Status: COMPLETED